Tavlesse

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Динатриевая Fostamatinib

Available from:

Instituto Grifols S.A.

ATC code:

B02BX

INN (International Name):

fostamatinib

Therapeutic group:

Druge sistemske кровоостанавливающие

Therapeutic area:

Trombocitopenija

Therapeutic indications:

Tavlesse je indiciran za liječenje kronične imunološki тромбоцитопении (IHS) u odraslih bolesnika, vatrostalne standardnim tretmanima na druge metode liječenja.

Product summary:

Revision: 5

Authorization status:

odobren

Authorization date:

2020-01-09

Patient Information leaflet

                                32
B. UPUTA O LIJEKU
33
UPUTA O LIJEKU: INFORMACIJE ZA BOLESNIKA
TAVLESSE 100 MG FILMOM OBLOŽENE TABLETE
TAVLESSE 150 MG FILMOM OBLOŽENE TABLETE
fostamatinibdinatrij heksahidrat
Ovaj je lijek pod dodatnim praćenjem. Time se omogućuje brzo
otkrivanje novih sigurnosnih
informacija. Prijavom svih sumnji na nuspojavu i Vi možete pomoći.
Za postupak prijavljivanja
nuspojava, pogledajte dio 4.
PAŽLJIVO PROČITAJTE CIJELU UPUTU PRIJE NEGO POČNETE UZIMATI OVAJ
LIJEK JER SADRŽI VAMA VAŽNE
PODATKE.

Sačuvajte ovu uputu. Možda ćete je trebati ponovno pročitati.

Ako imate dodatnih pitanja, obratite se liječniku, ljekarniku ili
medicinskoj sestri.

Ovaj je lijek propisan samo Vama. Nemojte ga davati drugima. Može im
naškoditi, čak i ako su
njihovi znakovi bolesti jednaki Vašima.

Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti
liječnika, ljekarnika ili medicinsku
sestru. To uključuje i svaku moguću nuspojavu koja nije navedena u
ovoj uputi. Vidjeti dio 4.
ŠTO SE NALAZI U OVOJ UPUTI:
1.
Što je TAVLESSE i za što se koristi
2.
Što morate znati prije nego počnete uzimati TAVLESSE
3.
Kako uzimati TAVLESSE
4.
Moguće nuspojave
5.
Kako čuvati TAVLESSE
6.
Sadržaj pakiranja i druge informacije
1.
ŠTO JE TAVLESSE I ZA ŠTO SE KORISTI
ŠTO JE TAVLESSE
TAVLESSE sadrži djelatnu tvar fostamatinib. On ciljano djeluje na
enzim naziva tirozin kinaza
slezene, koji ima važnu ulogu u uništavanju trombocita. Na taj
način TAVLESSE ograničava
uništavanje trombocita posredstvom imunosnog sustava i povećava broj
trombocita u tijelu. To
pridonosi smanjenju rizika od teškog krvarenja.
ZA ŠTO SE TAVLESSE KORISTI
TAVLESSE se primjenjuje u liječenju odraslih osoba s niskim brojem
trombocita zbog kronične
imunotrombocitopenije (ITP) kada prethodno liječenje ITP-a nije
djelovalo dovoljno dobro. ITP je
autoimuna bolest kod koje imunosni sustav tijela napada i uništava
trombocite u krvi. Trombociti su
potrebni kako bi pomogli u stvaranju ugrušaka i zaustavljanju
krvarenja.
2.
ŠTO MORATE Z
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOG I.
SAŽETAK OPISA SVOJSTAVA LIJEKA
2
Ovaj je lijek pod dodatnim praćenjem. Time se omogućuje brzo
otkrivanje novih sigurnosnih
informacija. Od zdravstvenih radnika se traži da prijave svaku sumnju
na nuspojavu za ovaj lijek. Za
postupak prijavljivanja nuspojava vidjeti dio 4.8.
1.
NAZIV LIJEKA
TAVLESSE 100 mg filmom obložene tablete
TAVLESSE 150 mg filmom obložene tablete
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
TAVLESSE 100 mg filmom obložene tablete
Jedna filmom obložena tableta sadrži 126,2 mg fostamatinibdinatrij
heksahidrata, što je istovjetno
100 mg fostamatiniba.
_Pomoćna(e) tvar(i) s poznatim učinkom _
Jedna tableta od 100 mg sadrži 23 mg natrija (iz pomoćnih tvari i
fostamatinibdinatrij heksahidrata).
TAVLESSE 150 mg filmom obložene tablete
Jedna filmom obložena tableta sadrži 189,3 mg fostamatinibdinatrij
heksahidrata, što je istovjetno
150 mg fostamatiniba.
_Pomoćna(e) tvar(i) s poznatim učinkom _
Jedna tableta od 150 mg sadrži 34 mg natrija (iz pomoćnih tvari i
fostamatinibdinatrij heksahidrata).
Za cjeloviti popis pomoćnih tvari vidjeti dio 6.1.
3.
FARMACEUTSKI OBLIK
Filmom obložena tableta.
TAVLESSE 100 mg filmom obložene tablete
Okrugla bikonveksna, tamnonarančasta, filmom obložena tableta
promjera otprilike 9,0 mm s
utisnutim „100” na jednoj strani i „R” na drugoj strani.
TAVLESSE 150 mg filmom obložene tablete
Ovalna, bikonveksna, svijetlonarančasta, filmom obložena tableta
veličine otprilike 7,25 mm x 14,5
mm s utisnutim „150” na jednoj strani i „R” na drugoj strani.
4.
KLINIČKI PODATCI
4.1.
TERAPIJSKE INDIKACIJE
TAVLESSE je indiciran za liječenje kronične imunotrombocitopenije
(ITP) u odraslih bolesnika koji
su refraktorni na druge terapije (vidjeti dio 5.1).
4.2.
DOZIRANJE I NAČIN PRIMJENE
Liječenje fostamatinibom treba započeti i nadzirati liječnik s
iskustvom u liječenju hematoloških
bolesti.
_ _
3
_Doziranje _
Doziranje fostamatiniba mora se prilagoditi pojedincu na temelju broja
trombocita bolesnika. Treba
koristiti najnižu doz
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 12-09-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 12-09-2022
Public Assessment Report Public Assessment Report Bulgarian 11-02-2020
Patient Information leaflet Patient Information leaflet Spanish 12-09-2022
Public Assessment Report Public Assessment Report Spanish 11-02-2020
Patient Information leaflet Patient Information leaflet Czech 12-09-2022
Public Assessment Report Public Assessment Report Czech 11-02-2020
Patient Information leaflet Patient Information leaflet Danish 12-09-2022
Public Assessment Report Public Assessment Report Danish 11-02-2020
Patient Information leaflet Patient Information leaflet German 12-09-2022
Public Assessment Report Public Assessment Report German 11-02-2020
Patient Information leaflet Patient Information leaflet Estonian 12-09-2022
Public Assessment Report Public Assessment Report Estonian 11-02-2020
Patient Information leaflet Patient Information leaflet Greek 12-09-2022
Public Assessment Report Public Assessment Report Greek 11-02-2020
Patient Information leaflet Patient Information leaflet English 12-09-2022
Public Assessment Report Public Assessment Report English 11-02-2020
Patient Information leaflet Patient Information leaflet French 12-09-2022
Public Assessment Report Public Assessment Report French 11-02-2020
Patient Information leaflet Patient Information leaflet Italian 12-09-2022
Public Assessment Report Public Assessment Report Italian 11-02-2020
Patient Information leaflet Patient Information leaflet Latvian 12-09-2022
Public Assessment Report Public Assessment Report Latvian 11-02-2020
Patient Information leaflet Patient Information leaflet Lithuanian 12-09-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 12-09-2022
Public Assessment Report Public Assessment Report Lithuanian 11-02-2020
Patient Information leaflet Patient Information leaflet Hungarian 12-09-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 12-09-2022
Public Assessment Report Public Assessment Report Hungarian 11-02-2020
Patient Information leaflet Patient Information leaflet Maltese 12-09-2022
Public Assessment Report Public Assessment Report Maltese 11-02-2020
Patient Information leaflet Patient Information leaflet Dutch 12-09-2022
Public Assessment Report Public Assessment Report Dutch 11-02-2020
Patient Information leaflet Patient Information leaflet Polish 12-09-2022
Public Assessment Report Public Assessment Report Polish 11-02-2020
Patient Information leaflet Patient Information leaflet Portuguese 12-09-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 12-09-2022
Public Assessment Report Public Assessment Report Portuguese 11-02-2020
Patient Information leaflet Patient Information leaflet Romanian 12-09-2022
Public Assessment Report Public Assessment Report Romanian 11-02-2020
Patient Information leaflet Patient Information leaflet Slovak 12-09-2022
Public Assessment Report Public Assessment Report Slovak 11-02-2020
Patient Information leaflet Patient Information leaflet Slovenian 12-09-2022
Summary of Product characteristics Summary of Product characteristics Slovenian 12-09-2022
Public Assessment Report Public Assessment Report Slovenian 11-02-2020
Patient Information leaflet Patient Information leaflet Finnish 12-09-2022
Public Assessment Report Public Assessment Report Finnish 11-02-2020
Patient Information leaflet Patient Information leaflet Swedish 12-09-2022
Public Assessment Report Public Assessment Report Swedish 11-02-2020
Patient Information leaflet Patient Information leaflet Norwegian 12-09-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 12-09-2022
Patient Information leaflet Patient Information leaflet Icelandic 12-09-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 12-09-2022

Search alerts related to this product

View documents history